Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 8/20 | 0.41 |
| ▸ | ITGA2B | P08514 | 8/20 | 0.41 |
| ▸ | ITGB1 | P05556 | 2/20 | 0.41 |
| ▸ | ITGA4 | P13612 | 2/20 | 0.41 |
| ▸ | F2 | P00734 | 3/20 | 0.40 |
| ▸ | APLNR | P35414 | 1/20 | 0.40 |
| ▸ | REN | P00797 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | CHRNA1 | P02708 | 1/20 | 0.38 |
| ▸ | CHRNG | P07510 | 1/20 | 0.38 |
| ▸ | CHRNB1 | P11230 | 1/20 | 0.38 |
| ▸ | CHRND | Q07001 | 1/20 | 0.38 |
| ▸ | NTMT1 | Q9BV86 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21350917 | 0.92 | APLNR (0.40) | ITGB3ITGA2BITGB1ITGA4F2 | |
| SCHEMBL19681264 | 0.90 | POLB (0.44) | ITGB3ITGA2BF2APLNRPOLB | |
| SCHEMBL21166989 | 0.88 | ACE (0.45) | ITGB3ITGA2BITGB1ITGA4F2 | |
| SCHEMBL21166966 | 0.86 | ITGB1 (0.44) | ITGB3ITGA2BITGB1ITGA4F2 | |
| SCHEMBL21167115 | 0.86 | ITGB1 (0.44) | ITGB3ITGA2BITGB1ITGA4F2 | |
| SCHEMBL21167022 | 0.86 | APLNR (0.46) | ITGB3ITGA2BITGB1ITGA4F2 | |
| SCHEMBL21339699 | 0.85 | ITGB1 (0.39) | ITGB1ITGA4F2APLNRREN | |
| SCHEMBL21347008 | 0.84 | CHRNA1 (0.55) | F2RENCHRNA1CHRNGCHRNB1 | |
| SCHEMBL21350916 | 0.83 | TSHR (0.39) | ITGB1ITGA4F2APLNRREN | |
| SCHEMBL19681206 | 0.82 | TSHR (0.54) | F2POLBTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210401943-A1 | COMPOSITIONS IN THE FORM OF AN INJECTABLE AQUEOUS SOLUTION COMPRISING AMYLIN, AN AMYLIN AGONIST RECEPTOR OR AN AMYLIN ANALOGUE AND A CO-POLYAMINO ACID | ADOCIA (FR) | 2021-12-30 | — | — | US | disclosed |
| US-20210386830-A1 | COMPOSITIONS IN THE FORM OF AN INJECTABLE AQUEOUS SOLUTION COMPRISING HUMAN GLUCAGON AND A CO-POLYAMINO ACID | ADOCIA (FR) | 2021-12-16 | — | — | US | disclosed |
| US-11191812-B2 | Compositions in the form of an injectable aqueous solution comprising human glucagon and a co-polyamino acid | ADOCIA (FR) | 2021-12-07 | — | — | US | disclosed |
| US-11129877-B2 | Compositions in the form of an injectable aqueous solution comprising amylin, an amylin agonist receptor or an amylin analogue and a co-polyamino acid | ADOCIA (FR) | 2021-09-28 | — | — | US | disclosed |
| US-20200306379-A1 | INJECTABLE PH 7 SOLUTION COMPRISING AT LEAST ONE BASAL INSULIN HAVING A PI FROM 5.8 TO 8.5 AND A CO-POLYAMINO ACID BEARING CARBOXYLATE CHARGES AND HYDROPHOBIC RADICALS | ADOCIA (FR) | 2020-10-01 | — | — | US | disclosed |
| US-20190328842-A1 | COMPOSITIONS IN THE FORM OF AN INJECTABLE AQUEOUS SOLUTION COMPRISING AMYLIN, AN AMYLIN AGONIST RECEPTOR OR AN AMYLIN ANALOGUE AND A CO-POLYAMINO ACID | ADOCIA (FR) | 2019-10-31 | — | — | US | disclosed |
| US-20190275109-A1 | COMPOSITIONS IN THE FORM OF AN INJECTABLE AQUEOUS SOLUTION COMPRISING HUMAN GLUCAGON AND A CO-POLYAMINO ACID | ADOCIA (FR) | 2019-09-12 | — | — | US | disclosed |
| US-20190216931-A1 | INJECTABLE PH 7 SOLUTION COMPRISING AT LEAST ONE BASAL INSULIN HAVING A PI FROM 5.8 TO 8.5 AND A CO-POLYAMINO ACID BEARING CARBOXYLATE CHARGES AND HYDROPHOBIC RADICALS | ADOCIA (FR) | 2019-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11191812-B2 | Compositions in the form of an injectable aqueous solution comprising human glucagon and a co-polyamino acid | GCG, GIPR, GLP1R | ITGB3 3010/4885ITGA2B 4164/4885ITGB1 4576/4885 |
| US-20190275109-A1 | COMPOSITIONS IN THE FORM OF AN INJECTABLE AQUEOUS SOLUTION COMPRISING HUMAN GLUCAGON AND A CO-POLYAMINO ACID | GCG, GIPR, GLP1R | ITGB3 2874/4885ITGA2B 3903/4885ITGB1 4540/4885 |
| US-11129877-B2 | Compositions in the form of an injectable aqueous solution comprising amylin, an amylin agonist receptor or an amylin analogue and a co-polyamino acid | IAPP, GLP1R, INSR | ITGB3 2934/4885ITGA2B 2686/4885ITGB1 3600/4885 |
| US-20200306379-A1 | INJECTABLE PH 7 SOLUTION COMPRISING AT LEAST ONE BASAL INSULIN HAVING A PI FROM 5.8 TO 8.5 AND A CO-POLYAMINO ACID BEARING CARBOXYLATE CHARGES AND HYDROPHOBIC RADICALS | IAPP, INSR, IGFBP5 | ITGB3 2335/4885ITGA2B 3365/4885ITGB1 3057/4885 |
| US-20190216931-A1 | INJECTABLE PH 7 SOLUTION COMPRISING AT LEAST ONE BASAL INSULIN HAVING A PI FROM 5.8 TO 8.5 AND A CO-POLYAMINO ACID BEARING CARBOXYLATE CHARGES AND HYDROPHOBIC RADICALS | IAPP, INSR, IGFBP5 | ITGB3 2335/4885ITGA2B 3365/4885ITGB1 3057/4885 |
| US-20190328842-A1 | COMPOSITIONS IN THE FORM OF AN INJECTABLE AQUEOUS SOLUTION COMPRISING AMYLIN, AN AMYLIN AGONIST RECEPTOR OR AN AMYLIN ANALOGUE AND A CO-POLYAMINO ACID | IAPP, GLP1R, INSR | ITGB3 2934/4885ITGA2B 2686/4885ITGB1 3600/4885 |
| US-20210386830-A1 | COMPOSITIONS IN THE FORM OF AN INJECTABLE AQUEOUS SOLUTION COMPRISING HUMAN GLUCAGON AND A CO-POLYAMINO ACID | GCG, GIPR, GLP1R | ITGB3 3010/4885ITGA2B 4164/4885ITGB1 4576/4885 |
| US-20210401943-A1 | COMPOSITIONS IN THE FORM OF AN INJECTABLE AQUEOUS SOLUTION COMPRISING AMYLIN, AN AMYLIN AGONIST RECEPTOR OR AN AMYLIN ANALOGUE AND A CO-POLYAMINO ACID | IAPP, GLP1R, INSR | ITGB3 2934/4885ITGA2B 2686/4885ITGB1 3600/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.